Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-proBNP-guided secondary prevention after acute coronary syndrome
ACTRN12618002005235Phase 4Completed
- Sponsor
- Professor Rob Doughty
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of carvedilol in acute coronary syndrome (ACS) and cardiac morbidity (2 arms), sponsored by Professor Rob Doughty. Primary endpoint: Maximum tolerated dosages of ACEI/ARB and beta-blocker. Started Dec 2018; status: completed.
02
Drugs
carvedilol
03
Conditions
acute coronary syndrome (ACS)cardiac morbidity
Beyond the preview
Go deeper on ACTRN12618002005235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618002005235.